MiR-140 Resensitizes Cisplatin-Resistant NSCLC Cells to Cisplatin Treatment Through the SIRT1/ROS/JNK Pathway

References

• Yao W, Wang L, Huang H, et al. All-trans retinoic acid reduces cancer stem cell-like cell-mediated resistance to gefitinib in NSCLC adenocarcinoma cells. BMC Cancer. 2020;20(1):315. doi:10.1186/s12885-020-06818-032293355
   PubMed Web of Science ®Google Scholar
• Yan M, Wang W, Zhou J, et al. Knockdown of PLAT enhances the anticancer effect of gefitinib in non-small cell lung cancer. J Thorac Dis. 2020;12(3):712–723. doi:10.21037/jtd.2019.12.10632274137
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7–30. doi:10.3322/caac.2159031912902
   PubMed Web of Science ®Google Scholar
• Allemani C, Weir HK, Carreira H, et al. CONCORD Working Group. Global surveillance of cancer survival 1995-2009: analysis of individual data for 25,676,887 patients from 279 population-based registries in 67 countries (CONCORD-2). Lancet. 2015;385977. doi:10.1016/S0140-6736(14)62038-9
   Web of Science ®Google Scholar
• Kumar S, Saikia J, Kumar V, et al. Neoadjuvant chemotherapy followed by surgery in lung cancer: indian scenario. Curr Probl Cancer. 2020;44(3):100563. doi:10.1016/j.currproblcancer.2020.10056332265058
   PubMed Web of Science ®Google Scholar
• Kancharla H, Gundu N, Pathak N, et al. Cytotoxic chemotherapy in advanced non-small cell lung cancer with poor performance status: A retrospective analysis from routine clinical practice. Curr Probl Cancer. 2020;44(3):100550. doi:10.1016/j.currproblcancer.2020.10055031987521
   PubMed Web of Science ®Google Scholar
• Sun R, Wang R, Chang S, et al. Long Non-Coding RNA in drug resistance of non-small cell lung cancer: a mini review. Front Pharmacol. 2019;10:1457. doi:10.3389/fphar.2019.0145731920650
   PubMed Web of Science ®Google Scholar
• Rotow J, Bivona TG. Understanding and targeting resistance mechanisms in NSCLC. Nat Rev Cancer. 2017;17:637–658. doi:10.1038/nrc.2017.8429068003
   PubMed Web of Science ®Google Scholar
• Fennell DA, Summers Y, Cadranel J, et al. Cisplatin in the modern era: the backbone of first-line chemotherapy for non-small cell lung cancer. Cancer Treat Rev. 2016;44:42–50. doi:10.1016/j.ctrv.2016.01.00326866673
   PubMed Web of Science ®Google Scholar
• Liu X, Ma M, Duan X, Zhang H, Yang M. Knockdown of OCT4 may sensitize NSCLC cells to cisplatin. Clin Transl Oncol. 2017;19(5):587–592. doi:10.1007/s12094-016-1569-y27832473
   PubMed Web of Science ®Google Scholar
• Roh JL, Park JY, Kim EH. XI-011 enhances cisplatin-induced apoptosis by functional restoration of p53 in head and neck cancer. Apoptosis. 2014;19(11):1594–1602. doi:10.1007/s10495-014-1026-825113507
   PubMed Web of Science ®Google Scholar
• Hu J, Xu C, Cheng B, et al. Imperatorin acts as a cisplatin sensitizer via downregulating Mcl-1 expression in HCC chemotherapy. Tumour Biol. 2016;37(1):331–339. doi:10.1007/s13277-015-3591-z26219890
   PubMedGoogle Scholar
• Ying J, Zhou D, Gu T, Huang J, Liu H. Pretreatment albumin/fibrinogen ratio as a promising predictor for the survival of advanced non small-cell lung cancer patients undergoing first-line platinum-based chemotherapy. BMC Cancer. 2019;19(1):288. doi:10.1186/s12885-019-5490-y30925910
   PubMedGoogle Scholar
• Gridelli C, Morabito A, Cavanna L, et al. Cisplatin-Based First-Line Treatment of Elderly Patients With Advanced Non-Small-Cell Lung Cancer: joint Analysis of MILES-3 and MILES-4 Phase III Trials. J Clin Oncol. 2018;36(25):2585–2592. doi:10.1200/JCO.2017.76.839030028656
   PubMed Web of Science ®Google Scholar
• Moro M, Caiola E, Ganzinelli M, et al. Metformin Enhances Cisplatin-Induced Apoptosis and Prevents Resistance to Cisplatin in Co-mutated KRAS/LKB1 NSCLC. J Thorac Oncol. 2018;13(11):1692–1704. doi:10.1016/j.jtho.2018.07.10230149143
   PubMed Web of Science ®Google Scholar
• MacDonagh L, Gray SG, Breen E, et al. BBI608 inhibits cancer stemness and reverses cisplatin resistance in NSCLC. Cancer Lett. 2018;428:117–126. doi:10.1016/j.canlet.2018.04.00829653268
   PubMed Web of Science ®Google Scholar
• Quevillon Huberdeau M, Simard MJ. A guide to micro RNA -mediated gene silencing. FEBS J. 2019;286(4):642. doi:10.1111/febs.1466630267606
   PubMed Web of Science ®Google Scholar
• Treiber T, Treiber N, Meister G. Regulation of microRNA biogenesis and its crosstalk with other cellular pathways. Nat Rev Mol Cell Biol. 2019;20(1):5–20. doi:10.1038/s41580-018-0059-130228348
   PubMed Web of Science ®Google Scholar
• Gebert LFR, MacRae IJ. Regulation of microRNA function in animals. Nat Rev Mol Cell Biol. 2019;20(1):21–37. doi:10.1038/s41580-018-0045-730108335
   PubMed Web of Science ®Google Scholar
• Yang Z, Wang L. Regulation of microRNA expression and function by nuclear receptor signaling. Cell Biosci. 2011;1(1):31. doi:10.1186/2045-3701-1-3121936947
   PubMedGoogle Scholar
• Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell. 2009;136(2):215–233. doi:10.1016/j.cell.2009.01.00219167326
   PubMed Web of Science ®Google Scholar
• Zhu H, Yang J, Yang S. MicroRNA-103a-3p potentiates chemoresistance to cisplatin in non-small cell lung carcinoma by targeting neurofibromatosis 1. Exp Ther Med. 2020;19(3):1797–1805. doi:10.3892/etm.2020.841832104235
   PubMed Web of Science ®Google Scholar
• Ba Z, Zhou Y, Yang Z, Xu J, Zhang X. miR-324-5p upregulation potentiates resistance to cisplatin by targeting FBXO11 signalling in non-small cell lung cancer cells. J Biochem. 2019;166(6):517–527. doi:10.1093/jb/mvz06631778188
   PubMed Web of Science ®Google Scholar
• Fang Z, Yin S, Sun R, et al. miR-140-5p suppresses the proliferation, migration and invasion of gastric cancer by regulating YES1. Mol Cancer. 2017;16(1):139. doi:10.1186/s12943-017-0708-628818100
   PubMed Web of Science ®Google Scholar
• Zhang R, Zhu JC, Hu H, Lin QY, Shao W, Ji TH. MicroRNA-140-5p suppresses invasion and proliferation of glioma cells by targeting glutamate-ammonia ligase (GLUL). Neoplasma. 2020;67(02):371–378. doi:10.4149/neo_2020_190514N43231986891
   PubMedGoogle Scholar
• Ma J, Zhang F, Sun P. miR-140-3p impedes the proliferation of human cervical cancer cells by targeting RRM2 to induce cell-cycle arrest and early apoptosis. Bioorg Med Chem. 2020;28(3):115283. doi:10.1016/j.bmc.2019.11528331902649
   PubMed Web of Science ®Google Scholar
• Wu D, Zhang J, Lu Y, et al. miR-140-5p inhibits the proliferation and enhances the efficacy of doxorubicin to breast cancer stem cells by targeting Wnt1. Cancer Gene Ther. 2019;26(3–4):74–82. doi:10.1038/s41417-018-0035-030032164
   PubMed Web of Science ®Google Scholar
• Lu X, Liu R, Wang M, et al. MicroRNA-140 impedes DNA repair by targeting FEN1 and enhances chemotherapeutic response in breast cancer. Oncogene. 2020;39(1):234–247. doi:10.1038/s41388-019-0986-031471584
   PubMed Web of Science ®Google Scholar
• Flamini V, Jiang WG, Cui Y. Therapeutic Role of MiR-140-5p for the treatment of non-small cell lung cancer. Anticancer Res. 2017;37(8):4319–4327. doi:10.21873/anticanres.1182528739724
   PubMed Web of Science ®Google Scholar
• Liao W, Zongjie F, Zou Y, et al. MicroRNA-140-5p attenuated oxidative stress in cisplatin induced acute kidney injury by activating Nrf2/ARE pathway through a keap1-independent mechanism. Exp Cell Res. 2017;360(2):292–302. doi:10.1016/j.yexcr.2017.09.01928928081
   PubMed Web of Science ®Google Scholar
• Cheng Y, Takeuchi H, Sonobe Y, et al. Sirtuin 1 attenuates oxidative stress via upregulation of superoxide dismutase 2 and catalase in astrocytes. J Neuroimmunol. 2014;269(1–2):38–43. doi:10.1016/j.jneuroim.2014.02.00124565075
   PubMed Web of Science ®Google Scholar
• Jiang K, Wang W, Jin X, Wang Z, Ji Z, Meng G. Silibinin, a natural flavonoid, induces autophagy via ROS-dependent mitochondrial dysfunction and loss of ATP involving BNIP3 in human MCF7 breast cancer cells. Oncol Rep. 2015;33(6):2711–2718. doi:10.3892/or.2015.391525891311
   PubMed Web of Science ®Google Scholar
• Wang S, Li H, Chen S, et al. Andrographolide induces apoptosis in human osteosarcoma cells via the ROS/JNK pathway. Int J Oncol. 2020;56(6):1417–1428. doi:10.3892/ijo.2020.503232236589
   PubMed Web of Science ®Google Scholar
• Lou L, Hu D, Chen S, et al. Protective role of JNK inhibitor SP600125 in sepsis-induced acute lung injury. Int J Clin Exp Pathol. 2019;12(2):528–538.31933857
   PubMed Web of Science ®Google Scholar
• Qian Y, Wu X, Wang H, Hou G, Han X, Song W. MicroRNA-4290 suppresses PDK1-mediated glycolysis to enhance the sensitivity of gastric cancer cell to cisplatin. Braz J Med Biol Res. 2020;53(5):e9330. doi:10.1590/1414-431X2020933032321153
   PubMed Web of Science ®Google Scholar
• Yang S, Li Z, Luo R. miR-34c targets MET to improve the anti-tumor effect of cisplatin on ovarian cancer. Onco Targets Ther. 2020;13:2887–2897. doi:10.2147/OTT.S23942532308421
   PubMed Web of Science ®Google Scholar
• Lin XJ, Liu H, Li P, et al. miR-936 suppresses cell proliferation, invasion, and drug resistance of laryngeal squamous cell carcinoma and targets gpr78. Mir-936 suppresses cell proliferation, invasion, and drug resistance of laryngeal squamous cell carcinoma and targets GPR78. Front Oncol. 2020;10:60. doi:10.3389/fonc.2020.0006032117723
   PubMed Web of Science ®Google Scholar
• Su X, Wang B, Wang Y, Wang B. Inhibition of TRIM32 induced by miR-519d increases the sensitivity of colorectal cancer cells to cisplatin. Onco Targets Ther. 2020;13:277–289. doi:10.2147/OTT.S23594032021274
   PubMed Web of Science ®Google Scholar
• Michan S, Sinclair D. Sirtuins in mammals: insights into their biological function. Biochem J. 2017;404(1):1–13. doi:10.1042/BJ20070140
   Google Scholar
• Chen HC, Jeng YM, Yuan RH, Hsu HC, Chen YL. SIRT1 promotes tumorigenesis and resistance to chemotherapy in hepatocellular carcinoma and its expression predicts poor prognosis. Ann Surg Oncol. 2012;19(6):2011–2019. doi:10.1245/s10434-011-2159-422146883
   PubMed Web of Science ®Google Scholar
• Jian KL, Zhang C, Shang ZC, Yang L, Kong LY. Eucalrobusone C suppresses cell proliferation and induces ROS-dependent mitochondrial apoptosis via the p38 MAPK pathway in hepatocellular carcinoma cells. Phytomedicine. 2017;25:71–82. doi:10.1016/j.phymed.2016.12.01428190473
   PubMed Web of Science ®Google Scholar
• Elangovan S, Ramachandran S, Venkatesan N, et al. SIRT1 is essential for oncogenic signaling by estrogen/estrogen receptor α in breast cancer. Cancer Res. 2011;71(21):6654–6664. doi:10.1158/0008-5472.CAN-11-144621920899
   PubMed Web of Science ®Google Scholar
• Bae HJ, Noh JH, Kim JK, et al. MicroRNA-29c functions as a tumor suppressor by direct targeting oncogenic SIRT1 in hepatocellular carcinoma. Oncogene. 2014;33(20):2557–2567. doi:10.1038/onc.2013.21623728341
   PubMed Web of Science ®Google Scholar
• Cheng F, Su L, Yao C, et al. SIRT1 promotes epithelial-mesenchymal transition and metastasis in colorectal cancer by regulating Fra-1 expression. Cancer Lett. 2016;375(2):274–283. doi:10.1016/j.canlet.2016.03.01026975631
   PubMed Web of Science ®Google Scholar
• Shu Y, Ren L, Xie B, Liang Z, Chen J. MiR-204 enhances mitochondrial apoptosis in doxorubicin-treated prostate cancer cells by targeting SIRT1/p53 pathway. Oncotarget. 2017;8(57):97313–97322. doi:10.18632/oncotarget.2196029228612
   PubMedGoogle Scholar
• Liu H, Cheng XH. MiR-29b reverses oxaliplatin-resistance in colorectal cancer by targeting SIRT1. Oncotarget. 2018;9(15):12304–12315. doi:10.18632/oncotarget.2438029552311
   PubMedGoogle Scholar
• Ji L, Zhong B, Jiang X, et al. Actein induces autophagy and apoptosis in human bladder cancer by potentiating ROS/JNK and inhibiting AKT pathways. Oncotarget. 2017;8(68):112498–112515. doi:10.18632/oncotarget.2227429348843
   PubMedGoogle Scholar
• Zhou G, Yang Z, Wang X, Tao R, Zhou Y. TRAIL enhances shikonin induced apoptosis through ROS/JNK signaling in cholangiocarcinoma cells. Cell Physiol Biochem. 2017;42(3):1073–1086. doi:10.1159/00047875828662515
   PubMedGoogle Scholar